Improved Interferon In Trial
Submitted by art on Mon, 2008-06-30 06:42.
BaroFold Inc. announced that it has initiated a two-stage Phase 1, repeat dosing, single-center, double-blinded study in up to sixty healthy volunteers to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of BaroFeron(TM) (IFN beta-1b).
It will be interesting to see if this improves the effects of the drug on MS. Once they test in people with MS, that is.